ProfileGDS4814 / ILMN_1728934
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 96% 97% 97% 97% 97% 98% 97% 96% 96% 97% 97% 96% 97% 96% 96% 97% 96% 97% 97% 97% 96% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)1262.8596
GSM780708Untreated after 4 days (C2_1)1360.3597
GSM780709Untreated after 4 days (C3_1)1652.7497
GSM780719Untreated after 4 days (C1_2)1483.4897
GSM780720Untreated after 4 days (C2_2)1309.6497
GSM780721Untreated after 4 days (C3_2)1745.1598
GSM780710Trastuzumab treated after 4 days (T1_1)1293.8197
GSM780711Trastuzumab treated after 4 days (T2_1)1221.4396
GSM780712Trastuzumab treated after 4 days (T3_1)1136.8196
GSM780722Trastuzumab treated after 4 days (T1_2)1329.797
GSM780723Trastuzumab treated after 4 days (T2_2)1316.2397
GSM780724Trastuzumab treated after 4 days (T3_2)1070.5796
GSM780713Pertuzumab treated after 4 days (P1_1)1295.697
GSM780714Pertuzumab treated after 4 days (P2_1)1107.9396
GSM780715Pertuzumab treated after 4 days (P3_1)1249.5196
GSM780725Pertuzumab treated after 4 days (P1_2)1317.4797
GSM780726Pertuzumab treated after 4 days (P2_2)1233.7196
GSM780727Pertuzumab treated after 4 days (P3_2)1468.9497
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)1440.8197
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)1283.9797
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)1255.796
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)1392.1197
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)1353.5797